These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 35177165)
1. Comparison of Tsai HL; Chen YC; Yin TC; Su WC; Chen PJ; Chang TK; Li CC; Huang CW; Wang JY Oncol Res; 2022 May; 29(1):47-61. PubMed ID: 35177165 [No Abstract] [Full Text] [Related]
2. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105 [TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY Trials; 2016 Jan; 17():46. PubMed ID: 26811156 [TBL] [Abstract][Full Text] [Related]
4. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762 [TBL] [Abstract][Full Text] [Related]
5. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211 [No Abstract] [Full Text] [Related]
6. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570 [TBL] [Abstract][Full Text] [Related]
7. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508 [TBL] [Abstract][Full Text] [Related]
8. Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous Tsai HL; Chen PJ; Chen YC; Li CC; Chang TK; Su WC; Yin TC; Huang CW; Wang JY J Int Med Res; 2022 Jul; 50(7):3000605221110697. PubMed ID: 35822291 [TBL] [Abstract][Full Text] [Related]
9. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912 [TBL] [Abstract][Full Text] [Related]
10. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072 [TBL] [Abstract][Full Text] [Related]
11. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. Sastre J; García-Alfonso P; Viéitez JM; Cano MT; Rivera F; Reina-Zoilo JJ; Salud-Salvia A; Quintero G; Robles-Díaz L; Safont MJ; La Casta A; Gil S; Polo E; Asensio-Martínez E; García-Paredes B; López RL; Guillot M; Valladares-Ayerbes M; Aranda E; Díaz-Rubio E; ESMO Open; 2021 Apr; 6(2):100062. PubMed ID: 33711671 [TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412 [TBL] [Abstract][Full Text] [Related]
14. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. Iwasa S; Muro K; Morita S; Park YS; Nakamura M; Kotaka M; Nishina T; Matsuoka H; Ahn JB; Lee KW; Hong YS; Han SW; Cho SH; Zhang DS; Fang WJ; Bai L; Yuan XL; Yuan Y; Yamada Y; Sakamoto J; Kim TW Cancer Sci; 2021 Nov; 112(11):4669-4678. PubMed ID: 34327766 [TBL] [Abstract][Full Text] [Related]
15. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156 [TBL] [Abstract][Full Text] [Related]
16. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865 [TBL] [Abstract][Full Text] [Related]
17. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang. Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830 [TBL] [Abstract][Full Text] [Related]
18. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929 [TBL] [Abstract][Full Text] [Related]
20. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. Burge M; Semira C; Lee B; Lee M; Kosmider S; Wong R; Shapiro J; Ma B; Dean AP; Zimet AS; Steel SA; Lok SW; Torres J; Eastgate M; Wong HL; Gibbs P Clin Colorectal Cancer; 2018 Sep; 17(3):e593-e599. PubMed ID: 29958812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]